UVI 3003
CAS: 847239-17-2
Ref. 3D-XIB23917
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire | |
| 100mg | To inquire |
Product Information
- 3-[4-Hydroxy-3-(5,5,8,8-Tetramethyl-3-Pentoxy-6,7-Dihydronaphthalen-2-Yl)Phenyl]Prop-2-Enoic Acid
UVI 3003 is a drug that is being developed for the treatment of cancer. It has been shown to activate the transcription factor, RAR-related orphan receptor alpha (RARα), which regulates the expression of basic proteins, fatty acids, and growth factors. UVI 3003 also activates Toll-like receptors (TLR) and increases the expression of TLR4 and TLR9. These receptors are responsible for initiating an immune response against bacteria in cells. The activation of TLR leads to a downregulation of these receptors, which leads to a reduction in inflammation caused by infection with bacteria. UVI 3003 has been shown to reposition drugs that have already been approved for other indications because it has the ability to inhibit cancer cell proliferation in vitro.
Chemical properties
Technical inquiry about: 3D-XIB23917 UVI 3003
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
